HOFFMANN LA ROCHE
Roche Vs Natco: Supreme Court clears decks for launch of Natco Pharma's Risdiplam generic in India
The Supreme Court has allowed Natco Pharma to launch its generic version of the spinal muscular atrophy drug Risdiplam in India, dismissing F. Hoffmann-La Roche's appeal. The court upheld the Delhi High Court's decision, which prioritized public access to the life-saving medication at a significantly lower price.
Roche moves SC against Natco’s launch of generic Risdiplam in India
F. Hoffmann-La Roche AG has approached the Supreme Court. This follows a Delhi High Court decision permitting Natco Pharma to introduce a generic version of Risdiplam. Risdiplam treats spinal muscular atrophy. The High Court rejected Roche's plea to halt Natco's manufacturing. Natco plans to sell the drug at a significantly lower price.
Delhi HC allows Natco Pharma to launch risdiplam, rejects Roche plea
The Delhi High Court has permitted Natco Pharma to launch its affordable generic version of risdiplam, a crucial drug for spinal muscular atrophy. This decision overturns a previous stay, allowing Natco to offer the medication at a significantly lower price than Swiss multinational Roche's imported Evrysdi. Roche expressed disappointment, emphasizing the importance of patent protection for innovation.
Delhi HC asks Natco Pharma to pause Risdiplam launch amid patent dispute
The Delhi High Court has ordered Natco Pharma to maintain status quo on the launch of Risdiplam until April 2. Roche, which holds the patent for the drug, sought an injunction to prevent Natco from manufacturing it in India. The court highlighted the public interest in making the drug affordable.
Supreme Court asks Zydus Lifesciences to approach Delhi HC over ban on selling breast cancer drug Sigrima
The Supreme Court has instructed Zydus Lifesciences to approach the Delhi High Court. Zydus is seeking relief from an order that prevents the sale of its breast cancer drug, Sigrima. Swiss pharmaceutical giant, Roche, alleges that Sigrima is similar to its own cancer drug. Roche requested the court to prohibit Zydus from selling Sigrima.
Delhi HC allows Zydus Lifesciences to sell breast cancer drug Sigrima
The Delhi High Court division bench has allowed Zydus Lifesciences to sell its breast cancer drug Sigrima amidst accusations of it being similar to Roche's Perjeta. The court invalidated an earlier restraint order, noting no patent infringement by Zydus.
- Go To Page 1

2.39 crore COVID-19 tests conducted in India in August, says Minister of State for Health
So far, 1.41 crore of PPE Kits, 3.44 crore N-95 masks, 10.84 crore tablets of hydroxychloroquine, 30,796 ventilators and 1,02,400 oxygen cylinders have been supplied to states, union territories and central government hospitals.

Swiss drugmaker Roche says demand for Covid-19 tests exceeds production
"The demand exceeds our production," Christoph Franz was quoted as saying in Saturday's paper. The decision on where tests were shipped to depended, among other things, on infection rates and the availability of diagnostic equipment. Demand for its antibody tests, which determine whether people have ever been infected with the coronavirus, can be met as Roche has been boosting production, he said.

Call for patent removal, price cut of Covid-19 drugs and diagnostics
Over 20 civil society groups working on health rights have written to government to encourage innovation, remove patent barriers and bring down prices of key drugs and diagnostics used for Covid-19.

Roche says prostate cancer drug hit one trial goal, missed another
Swiss drugmaker Roche said on Friday its experimental medicine ipatasertib hit one goal of a late-stage clinical trial against a small slice of patients with a kind of prostate cancer but fell short in the overall study population.

Roche India head Lara Bezerra set to exit
A Roche India spokesperson confirmed the development and said an announcement for a new India head will be made soon. “Dec. 1 will be the date for Lara to end the assignment. During her tenure at Roche India, Lara successfully led the organization with passion and commitment and shaped the culture of the organization,”the statement added.

Alembic Pharma gets USFDA nod for seizure treatment drug
The approved product is therapeutically equivalent to the reference listed drug Klonopin orally disintegrating tablets of Hoffmann-La Roche, Inc.

Turkey says it will take over fight against IS after US pull-out
For Turkey, the step removes a source of friction with the United States. Erdogan has long castigated his NATO ally over its support for Syrian Kurdish YPG fighters against Islamic State.

Cipla gets USFDA nod for anti-viral eye infection drug for AIDS patients
The approved products is a generic therapeutic equivalent version of Roche's Valcyte.

CCI orders detailed probe against pharma major Roche
According to the CIC, Roche Group is dominant in the relevant market and can operate independently of the market forces.

Natco Pharma surges 7% on drug approval
The stock rose 7.33 per cent to hit a high of Rs 650.90 on BSE. Volumes more than doubled on the counter to 98,000 shares, compared with a two-week average of 54,000 shares.

Natco Pharma gets ANDA nod for Tamiflu's generic version
Tamiflu is used to treat the flu (influenza) in people 2 weeks of age and older who have had flu symptoms for no more than 2 days.

Natco settles patent suit with Gilead, others over Tamiflu
Natco Pharma and its partner Alvogen today said they have settled patent infringement suit with Gilead Sciences Inc and others over Tamiflu.

Aurobindo Pharma gets USFDA nod to market ulcer drug
The company's approved abbreviated new drug application (ANDA) is a generic version of AstraZeneca Pharmaceuticals' Prilosec capsules, it added.

Intas settles patent litigation with Hoffmann-La Roche for capecitabine tablet
Ahmedabad-based drug maker, Intas Pharmaceuticals Ltd and its US-based wholly owned subsidiary Accord Healthcare Inc. has entered into a settlement.
Delhi High Court dismisses Roche's patent suit against Cipla
The Delhi HC dismissed Hoffmann-La Roche's suit accusing Cipla of infringing the Swiss company's patent for its lung cancer medicine Tarceva.

Global swine flu kit makers gear up to meet demand
US-based Applied Biosystems and Swiss firm Roche Diagnostics , have said that they are ramping up their manufacturing capacities to meet rising demand for such kits used to detect H1N1 flu.
Pharma companies donate tamiflu
The Indian arm of Swiss pharma major Hoffmann-La Roche and Hyderabad-based Hetero Drugs have together donated one lakh dosages of Tamiflu medicine to government authorities.
WB soon to have a world class research facility for cancer
West Bengal will soon house a world-class research facility for cancer.
Roche to tap tissue diagnostic biz here
Roche Diagnostics India, a wholly-owned arm of Swiss pharma and diagnostics major F Hoffmann-La Roche, plans to expand its India footprint by foraying into the tissue diagnostic segment.
Govt upholds patent of Roche’s Hepatitis drug Pegasys
The government has upheld the patent of Swiss drug major Hoffmann La Roche’s Hepatitis C drug, Pegasys. It is the first drug to be given patent in India after the country adopted new patent regime in 2005.
Dr Reddy's Laboratories wins round 1 of patent war
US court dismisses one of the three patent claims made by Roche for Boniva; DRL still in litigation for two other listed patents.
HC restrains Cipla from exporting anti-cancer drug
The Delhi High Court on Tuesday restrained pharma major Cipla from exporting ‘Tarceva’ to those countries where Swiss company Hoffmann La Roche has patent registration for the anti-cancer drug.
HC restrains Cipla from exporting anti-cancer drug
The Delhi High Court today restrained pharma major Cipla from exporting 'Tarceva' to those countries where Swiss company Hoffmann La Roche has patent registration for the anti-cancer drug.
Load More